Mirum Pharmaceuticals (MIRM) Narrowing Losses Challenge Bearish Profitability Narratives In FY 2025 Results

Simply Wall St.02-27

AdvertisementFY 2025 results snapshot Mirum Pharmaceuticals (MIRM) has wrapped up FY 2025 with Q4 revenue of US$148.9 million and a basic EPS loss of US$0.11, alongside trailing twelve month revenue ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614695009?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-02-27 09:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614695009","market":"hk","top_or_hot":-1,"title":"Mirum Pharmaceuticals (MIRM) Narrowing Losses Challenge Bearish Profitability Narratives In FY 2025 Results","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementFY 2025 results snapshot Mirum Pharmaceuticals (MIRM) has wrapped up FY 2025 with Q4 revenue of US$148.9 million and a basic EPS loss of US$0.11, alongside trailing twelve month revenue ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/mirum-pharmaceuticals-mirm-narrowing-losses-challenge-bearis\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mirum Pharmaceuticals (MIRM) Narrowing Losses Challenge Bearish Profitability Narratives In FY 2025 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMirum Pharmaceuticals (MIRM) Narrowing Losses Challenge Bearish Profitability Narratives In FY 2025 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-27 09:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/mirum-pharmaceuticals-mirm-narrowing-losses-challenge-bearis><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementFY 2025 results snapshot Mirum Pharmaceuticals (MIRM) has wrapped up FY 2025 with Q4 revenue of US$148.9 million and a basic EPS loss of US$0.11, alongside trailing twelve month revenue ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/mirum-pharmaceuticals-mirm-narrowing-losses-challenge-bearis\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MIRM","symbol_name":"Mirum Pharmaceuticals, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/mirum-pharmaceuticals-mirm-narrowing-losses-challenge-bearis","article_id":"2614695009","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/mirum-pharmaceuticals-mirm-narrowing-losses-challenge-bearis","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614695009","pubTimestamp":1772155887,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"FY 2025 results snapshot\nMirum Pharmaceuticals (MIRM) has wrapped up FY 2025 with Q4 revenue of US$148.9 million and a basic EPS loss of US$0.11, alongside trailing twelve month revenue of US$521.3 million and a full year basic EPS loss of US$0.47. Over recent quarters the company has seen revenue move from US$99.4 million in Q4 2024 to US$148.9 million in Q4 2025, while quarterly basic EPS has ranged between a loss of US$0.50 in Q4 2024 and a small profit of US$0.06 in Q3 2025. This latest...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"MIRM":"Mirum Pharmaceuticals, Inc.","BK4139":"生物科技"},"translate_title":"Mirum Pharmaceuticals(MIRM)亏损收窄挑战2025财年业绩中盈利能力的悲观叙述","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIRM":1.5},"content_text":"AdvertisementFY 2025 results snapshot Mirum Pharmaceuticals (MIRM) has wrapped up FY 2025 with Q4 revenue of US$148.9 million and a basic EPS loss of US$0.11, alongside trailing twelve month revenue of US$521.3 million and a full year basic EPS loss of US$0.47. Over recent quarters the company has seen revenue move from US$99.4 million in Q4 2024 to US$148.9 million in Q4 2025, while quarterly basic EPS has ranged between a loss of US$0.50 in Q4 2024 and a small profit of US$0.06 in Q3 2025. This latest report serves as another checkpoint on Mirum's path toward tighter margins and a clearer route to sustained profitability. See our full analysis for Mirum Pharmaceuticals. With the numbers on the table, the next step is to see how this revenue and EPS path lines up with the widely discussed growth and profitability narratives around Mirum and where those stories might need updating. See what the community is saying about Mirum Pharmaceuticals NasdaqGM:MIRM Earnings & Revenue History as at Feb 2026 Losses narrow on a US$23.4 million trailing deficit  On a trailing twelve month basis Mirum reported total revenue of US$521.3 million with a net loss of US$23.4 million and basic EPS of US$0.47 loss, compared with a trailing loss of US$87.9 million and EPS of US$1.85 loss at the end of FY 2024. What stands out for the bullish narrative is that this multi year pattern of reduced losses, cited at 10.9% a year, sits alongside forecasts for roughly 58.4% yearly earnings growth and revenue growth of 21.9%, yet the latest year still closed with a loss of US$23.4 million.\n     Supporters of the bullish view point to this gradual narrowing of losses as evidence of a path toward the forecast move from a current margin of 13.6% loss to a positive 12.9% margin in three years. However, the fact that Mirum is still loss making today is a reminder that those margin shifts are not visible in the reported numbers yet. At the same time, the step from quarterly profit of US$2.9 million in Q3 2025 back to a US$5.7 million loss in Q4 shows that profitability is still uneven from quarter to quarter. This can make the bullish straight line forecasts feel optimistic when you compare them to the actual earnings swings.    Supporters who think this improving loss profile points to a bigger upside story may want to see how the full bullish case lines up against these FY 2025 numbers before leaning too hard on forecasts. 🐂 Mirum Pharmaceuticals Bull Case Top line ramps while EPS remains choppy  Quarterly revenue has moved from US$90.4 million in Q3 2024 to US$148.9 million in Q4 2025, while basic EPS has bounced between a loss of US$0.50 in Q4 2024, a small profit of US$0.06 in Q3 2025, and a loss of US$0.11 in Q4 2025. Bears focus on this mix of strong revenue growth and uneven EPS to argue that even if revenue keeps rising, profitability might not follow the clean trajectory implied in forecasts that call for 22.8% annual revenue growth and margins improving from a 13.6% loss to a 12.9% profit over three years.\n     From that cautious angle, the swing from a quarterly profit in Q3 2025 back to a loss in Q4 gives ammunition to the idea that Mirum’s earnings are still heavily exposed to factors like R&D spending and reimbursement dynamics, so the forecast move to US$102.1 million of earnings by 2028 is not yet visible in the quarterly pattern. On the other hand, the fact that revenue has reached US$521.3 million on a trailing basis while losses are far smaller than the US$99.8 million level cited for twelve months ending Q3 2024 shows that earnings are moving in the direction that both bulls and the consensus expect, just with more noise than the bearish side likes.    P/S of 10.6x versus DCF value and insider signals  With a current share price of US$92.19 and trailing twelve month revenue of US$521.3 million, Mirum’s P/S sits at 10.6x, below the US biotechs industry average of 12.5x and the peer average of 41.5x, while the provided DCF fair value of US$363.75 per share is far above the current price. Critics highlight that this apparent discount to the US$121.80 analyst price target and the DCF fair value sits alongside shareholder dilution over the past year and meaningful insider selling in the last three months. These factors can pull in the opposite direction of the bullish valuation story.\n     That combination means investors are weighing a P/S that screens as cheaper than peers and a very high DCF fair value against the fact that insiders chose to sell shares recently and that the share count has increased, which are the kinds of signals bearish investors tend to treat as caution flags even when models imply upside. For someone looking at the stock\nNext Steps To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Mirum Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves. If this mix of bullish and cautious points leaves you unsure, it is a good moment to look at the full picture yourself and decide how you feel about the balance of risk and reward, starting with 4 key rewards and 2 important warning signs. See What Else Is Out There Mirum’s story still has clear weak spots, with choppy quarterly EPS, ongoing losses of US$23.4 million and insider selling alongside shareholder dilution. If that mix of uneven earnings and insider selling makes you cautious about concentration risk, it could be time to spread your attention across 80 resilient stocks with low risk scores that aim to keep potential shocks in check.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614695009","isCrawlerRequest":true}